Regulatory – Page 2 – Alligator Bioscience

2024-10-31

Regulatory

Nomination Committee appointed in respect of AGM 2025 in Alligator Bioscience AB

Lund, Sweden, October 31, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in prepa ...

2024-10-24

Regulatory

Recruitment completed of 450 µg/kg back-fill cohort in the mitazalimab OPTIMIZE-1 study in pancreatic cancer Positive interim Phase 1 ...

2024-07-112024-07-11

Regulatory

Substantial overall survival benefit and unprecedented Duration of Response reported in 18-month analysis from mitazalimab OPTIMIZE-1 Phase ...

2024-06-26

Regulatory

Median Overall Survival increased to 14.9 months and survival rate at 18 months was 36.2%, nearly twice as high as the 18.6% previously repo ...

2024-06-25

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2024-06-14

Regulatory

Lund, Sweden, June 14, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the appointment of Johan Giléus as ...

2024-05-07

Regulatory

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2024-05-06

Regulatory

Mitazalimab Phase 3 preparations underway following positive top-line results from OPTIMIZE-1 Phase 2 study in pancreatic cancer Positive in ...

2024-04-30

Regulatory

During April 2024, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the comp ...